Cargando…

Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison

BACKGROUND: Measuring specific anti-SARS-CoV-2 antibodies has become one of the main epidemiological tools to survey the ongoing SARS-CoV-2 pandemic, but also vaccination response. The WHO made available a set of well-characterized samples derived from recovered individuals to allow normalization be...

Descripción completa

Detalles Bibliográficos
Autores principales: Kroidl, Inge, Winter, Simon, Rubio-Acero, Raquel, Bakuli, Abhishek, Geldmacher, Christof, Eser, Tabea M., Déak, Flora, Horn, Sacha, Zielke, Anna, Ahmed, Mohamed I. M., Diepers, Paulina, Guggenbühl, Jessica, Frese, Jonathan, Bruger, Jan, Puchinger, Kerstin, Reich, Jakob, Falk, Philine, Markgraf, Alisa, Fensterseifer, Heike, Paunovic, Ivana, Thomschke, Angelika, Pritsch, Michael, Riess, Friedrich, Saathoff, Elmar, Hoelscher, Michael, Olbrich, Laura, Castelletti, Noemi, Wieser, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474769/
https://www.ncbi.nlm.nih.gov/pubmed/37658454
http://dx.doi.org/10.1186/s12985-023-02167-z
_version_ 1785100574580015104
author Kroidl, Inge
Winter, Simon
Rubio-Acero, Raquel
Bakuli, Abhishek
Geldmacher, Christof
Eser, Tabea M.
Déak, Flora
Horn, Sacha
Zielke, Anna
Ahmed, Mohamed I. M.
Diepers, Paulina
Guggenbühl, Jessica
Frese, Jonathan
Bruger, Jan
Puchinger, Kerstin
Reich, Jakob
Falk, Philine
Markgraf, Alisa
Fensterseifer, Heike
Paunovic, Ivana
Thomschke, Angelika
Pritsch, Michael
Riess, Friedrich
Saathoff, Elmar
Hoelscher, Michael
Olbrich, Laura
Castelletti, Noemi
Wieser, Andreas
author_facet Kroidl, Inge
Winter, Simon
Rubio-Acero, Raquel
Bakuli, Abhishek
Geldmacher, Christof
Eser, Tabea M.
Déak, Flora
Horn, Sacha
Zielke, Anna
Ahmed, Mohamed I. M.
Diepers, Paulina
Guggenbühl, Jessica
Frese, Jonathan
Bruger, Jan
Puchinger, Kerstin
Reich, Jakob
Falk, Philine
Markgraf, Alisa
Fensterseifer, Heike
Paunovic, Ivana
Thomschke, Angelika
Pritsch, Michael
Riess, Friedrich
Saathoff, Elmar
Hoelscher, Michael
Olbrich, Laura
Castelletti, Noemi
Wieser, Andreas
author_sort Kroidl, Inge
collection PubMed
description BACKGROUND: Measuring specific anti-SARS-CoV-2 antibodies has become one of the main epidemiological tools to survey the ongoing SARS-CoV-2 pandemic, but also vaccination response. The WHO made available a set of well-characterized samples derived from recovered individuals to allow normalization between different quantitative anti-Spike assays to defined Binding Antibody Units (BAU). METHODS: To assess sero-responses longitudinally, a cohort of ninety-nine SARS-CoV-2 RT-PCR positive subjects was followed up together with forty-five vaccinees without previous infection but with two vaccinations. Sero-responses were evaluated using a total of six different assays: four measuring anti-Spike proteins (converted to BAU), one measuring anti-Nucleocapsid proteins and one SARS-CoV-2 surrogate virus neutralization. Both cohorts were evaluated using the Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and the Roche Elecsys Anti-SARS-CoV-2 anti-S1 assay. RESULTS: In SARS-CoV-2-convalesce subjects, the BAU-sero-responses of Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and Roche Elecsys Anti-SARS-CoV-2 anti-S1 peaked both at 47 (43–51) days, the first assay followed by a slow decay thereafter (> 208 days), while the second assay not presenting any decay within one year. Both assay values in BAUs are only equivalent a few months after infection, elsewhere correction factors up to 10 are necessary. In contrast, in infection-naive vaccinees the assays perform similarly. CONCLUSION: The results of our study suggest that the establishment of a protective correlate or vaccination booster recommendation based on different assays, although BAU-standardised, is still challenging. At the moment the characteristics of the available assays used are not related, and the BAU-standardisation is unable to correct for that. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12985-023-02167-z.
format Online
Article
Text
id pubmed-10474769
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104747692023-09-03 Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison Kroidl, Inge Winter, Simon Rubio-Acero, Raquel Bakuli, Abhishek Geldmacher, Christof Eser, Tabea M. Déak, Flora Horn, Sacha Zielke, Anna Ahmed, Mohamed I. M. Diepers, Paulina Guggenbühl, Jessica Frese, Jonathan Bruger, Jan Puchinger, Kerstin Reich, Jakob Falk, Philine Markgraf, Alisa Fensterseifer, Heike Paunovic, Ivana Thomschke, Angelika Pritsch, Michael Riess, Friedrich Saathoff, Elmar Hoelscher, Michael Olbrich, Laura Castelletti, Noemi Wieser, Andreas Virol J Research BACKGROUND: Measuring specific anti-SARS-CoV-2 antibodies has become one of the main epidemiological tools to survey the ongoing SARS-CoV-2 pandemic, but also vaccination response. The WHO made available a set of well-characterized samples derived from recovered individuals to allow normalization between different quantitative anti-Spike assays to defined Binding Antibody Units (BAU). METHODS: To assess sero-responses longitudinally, a cohort of ninety-nine SARS-CoV-2 RT-PCR positive subjects was followed up together with forty-five vaccinees without previous infection but with two vaccinations. Sero-responses were evaluated using a total of six different assays: four measuring anti-Spike proteins (converted to BAU), one measuring anti-Nucleocapsid proteins and one SARS-CoV-2 surrogate virus neutralization. Both cohorts were evaluated using the Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and the Roche Elecsys Anti-SARS-CoV-2 anti-S1 assay. RESULTS: In SARS-CoV-2-convalesce subjects, the BAU-sero-responses of Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and Roche Elecsys Anti-SARS-CoV-2 anti-S1 peaked both at 47 (43–51) days, the first assay followed by a slow decay thereafter (> 208 days), while the second assay not presenting any decay within one year. Both assay values in BAUs are only equivalent a few months after infection, elsewhere correction factors up to 10 are necessary. In contrast, in infection-naive vaccinees the assays perform similarly. CONCLUSION: The results of our study suggest that the establishment of a protective correlate or vaccination booster recommendation based on different assays, although BAU-standardised, is still challenging. At the moment the characteristics of the available assays used are not related, and the BAU-standardisation is unable to correct for that. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12985-023-02167-z. BioMed Central 2023-09-01 /pmc/articles/PMC10474769/ /pubmed/37658454 http://dx.doi.org/10.1186/s12985-023-02167-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kroidl, Inge
Winter, Simon
Rubio-Acero, Raquel
Bakuli, Abhishek
Geldmacher, Christof
Eser, Tabea M.
Déak, Flora
Horn, Sacha
Zielke, Anna
Ahmed, Mohamed I. M.
Diepers, Paulina
Guggenbühl, Jessica
Frese, Jonathan
Bruger, Jan
Puchinger, Kerstin
Reich, Jakob
Falk, Philine
Markgraf, Alisa
Fensterseifer, Heike
Paunovic, Ivana
Thomschke, Angelika
Pritsch, Michael
Riess, Friedrich
Saathoff, Elmar
Hoelscher, Michael
Olbrich, Laura
Castelletti, Noemi
Wieser, Andreas
Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison
title Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison
title_full Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison
title_fullStr Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison
title_full_unstemmed Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison
title_short Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison
title_sort studying temporal titre evolution of commercial sars-cov-2 assays reveals significant shortcomings of using bau standardization for comparison
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474769/
https://www.ncbi.nlm.nih.gov/pubmed/37658454
http://dx.doi.org/10.1186/s12985-023-02167-z
work_keys_str_mv AT kroidlinge studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT wintersimon studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT rubioaceroraquel studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT bakuliabhishek studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT geldmacherchristof studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT esertabeam studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT deakflora studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT hornsacha studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT zielkeanna studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT ahmedmohamedim studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT dieperspaulina studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT guggenbuhljessica studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT fresejonathan studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT brugerjan studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT puchingerkerstin studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT reichjakob studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT falkphiline studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT markgrafalisa studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT fensterseiferheike studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT paunovicivana studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT thomschkeangelika studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT pritschmichael studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT riessfriedrich studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT saathoffelmar studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT hoelschermichael studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT olbrichlaura studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT castellettinoemi studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT wieserandreas studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison
AT studyingtemporaltitreevolutionofcommercialsarscov2assaysrevealssignificantshortcomingsofusingbaustandardizationforcomparison